Johnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE®

NEW BRUNSWICK, N.J., Feb. 12, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE® issuing a final rejection of the patent.

We have sixty days to respond to this action and will do so. Currently the '471 patent expires in September 2018. We believe the '471 patent is valid and, if necessary, will pursue all available appeals.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, challenges to the coverage and/or validity of the company's patents. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.) 

To view the original version on PR Newswire, visit:

SOURCE Johnson & Johnson

News Provided by Acquire Media